Reshma Kewalramani is CEO & President at VERTEX PHARMACEUTICALS INC / MA (VRTX). They have made 17 open-market trades across 1 company since 2018, most recently 2026-02-27.
CIK 0001735944
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $11.7M since 2021, against 15 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| VRTX | 98,278 | $49.1M |
| DNA | 186,002 | $1.9M |
| Total | $51.0M |
Shares reported on the most recent Form 4, priced at the 2026-03-03 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VRTX | SELL | 2026-02-27 | 2026-03-03 | $493.47 | $19.7M | -1.3% | -7.7% | -7.8% |
| VRTX | BUY | 2025-08-06 | 2025-08-07 | $389.58 | $7.8M | +3.6% | +4.8% | +10.6% |
| VRTX | SELL · 10b5-1 | 2024-11-08 | 2024-11-12 | $515.00 | $7.8M | -8.2% | -5.5% | -4.3% |
| VRTX | SELL · 10b5-1 | 2024-07-30 | 2024-08-01 | $505.00 | $7.7M | -4.9% | -3.2% | -3.3% |
| VRTX | SELL · 10b5-1 | 2024-07-22 | 2024-07-24 | $497.00 | $7.6M | -3.5% | -2.6% | -3.9% |
| VRTX | SELL · 10b5-1 | 2024-05-24 | 2024-05-29 | $457.00 | $715K | +10.1% | +6.7% | +9.4% |
| VRTX | SELL · 10b5-1 | 2024-05-20 | 2024-05-22 | $447.00 | $6.8M | +5.6% | +4.3% | +8.4% |
| VRTX | SELL · 10b5-1 | 2023-12-15 | 2023-12-19 | $407.00 | $7.0M | +1.7% | +7.2% | +1.8% |
| VRTX | SELL · 10b5-1 | 2023-12-13 | 2023-12-15 | $397.00 | $2.0M | -0.6% | +6.3% | -0.7% |
| VRTX | SELL · 10b5-1 | 2023-11-13 | 2023-11-15 | $377.00 | $1.9M | -1.0% | +17.1% | +18.6% |
| VRTX | SELL · 10b5-1 | 2023-07-17 | 2023-07-18 | $355.00 | $2.8M | -1.7% | -4.5% | +3.9% |
| VRTX | SELL · 10b5-1 | 2023-04-27 | 2023-05-01 | $339.07 | $2.2M | +1.6% | -6.2% | +2.1% |
| VRTX | SELL | 2023-01-25 | 2023-01-27 | $315.05 | $3.2M | -8.7% | -10.5% | +5.7% |
| VRTX | SELL | 2022-08-15 | 2022-08-17 | $305.06 | $7.1M | -6.1% | -3.4% | +1.8% |
| VRTX | SELL | 2022-06-24 | 2022-06-28 | $291.30 | $6.8M | +6.6% | +1.8% | +0.3% |
| VRTX | BUY | 2021-08-19 | 2021-08-23 | $195.65 | $3.9M | +0.2% | -7.3% | -8.7% |
| VRTX | SELL | 2020-08-06 | 2020-08-10 | $271.24 | $1.1M | +2.0% | -1.1% | -16.2% |
| VRTX | SELL · 10b5-1 | 2020-05-15 | 2020-05-19 | $284.17 | $28K | +0.6% | -2.0% | -3.9% |
| VRTX | SELL | 2020-05-06 | 2020-05-08 | $272.84 | $1.0M | +4.9% | -2.4% | +0.7% |
| VRTX | SELL | 2020-02-25 | 2020-02-26 | $233.62 | $1.5M | -3.9% | -4.9% | +16.6% |
| VRTX | SELL | 2020-02-18 | 2020-02-19 | $243.45 | $483K | -6.1% | -16.7% | +14.1% |
| VRTX | SELL | 2020-02-06 | 2020-02-07 | $239.34 | $962K | +2.5% | -8.2% | +12.9% |
| VRTX | SELL | 2019-11-25 | 2019-11-26 | $219.37 | $2.1M | +0.1% | +0.5% | +8.2% |
| VRTX | SELL · 10b5-1 | 2019-11-15 | 2019-11-19 | $205.95 | $13K | +2.8% | +1.4% | +14.5% |
| VRTX | SELL | 2019-11-08 | 2019-11-13 | $199.00 | $101K | +7.9% | +5.9% | +19.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.